ACULAR 0.5 %
KETOROLAC TROMETHAMINE : 0.5 % · DIN 01968300 · ABBVIE CORPORATION
Health Canada status: MARKETED
What is ACULAR?
ACULAR 0.5 % contains KETOROLAC TROMETHAMINE : 0.5 %. It is listed in the Health Canada Drug Product Database under DIN 01968300, held by ABBVIE CORPORATION, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 05-Oct-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 01968300 |
|---|---|
| Brand name | ACULAR |
| Generic / active ingredient | KETOROLAC TROMETHAMINE : 0.5 % |
| Manufacturer | ABBVIE CORPORATION |
| Strength | 0.5 % |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01BC05 KETOROLAC |
| AHFS class | 52:08.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 05-Oct-2023 |
| Original market date | 1992-12-31 00:00:00 |
Is KETOROLAC in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by AA PHARMA INC (Tier 3 Drug Shortages About & Resources), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code S01BC05 KETOROLAC. 3 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACUVAIL | 0.45 % | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02369362 |
| KETOROLAC | 0.5 % | SOLUTION | AA PHARMA INC | MARKETED | DIN 02245821 |
| ACULAR LS | 0.4 % | SOLUTION | ABBVIE CORPORATION | CANCELLED POST MARKET | DIN 02248722 |
| NU-KETOROLAC OPHTHALMIC SOLUTION | 0.5 % | SOLUTION | NU-PHARM INC | CANCELLED (UNRETURNED ANNUAL) | DIN 02336693 |
| RATIO-KETOROLAC | 0.5 % | SOLUTION | RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02247461 |
Who else supplies KETOROLAC worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. KETOROLAC appears in 48 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.